ChemicalBook >> CAS DataBase List >>Rucaparib

Rucaparib

CAS No.
283173-50-2
Chemical Name:
Rucaparib
Synonyms
Rucaparib Base;8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one;Rikapbu;AG-14447;AG014447;Rucaparib;AG 014447;PF-01367388;AG 014447;AG014447;Rucaparib impurity
CBNumber:
CB51475507
Molecular Formula:
C19H18FN3O
Molecular Weight:
323.36
MDL Number:
MFCD11977252
MOL File:
283173-50-2.mol
Last updated:2024-11-19 15:53:33

Rucaparib Properties

Melting point 187 - 189°C
Boiling point 625.2±55.0 °C(Predicted)
Density 1.281
storage temp. 2-8°C(protect from light)
solubility DMSO (Slightly), Methanol (Slightly)
form Yellow solid.
pka 14.10±0.20(Predicted)
color Pale Yellow to Yellow
FDA UNII 8237F3U7EH
ATC code L01XK03

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS08
Signal word  Warning
Hazard statements  H361
Precautionary statements  P201-P202-P281-P308+P313-P405-P501

Rucaparib price More Price(38)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 15643 Rucaparib ≥98% 283173-50-2 1mg $32 2024-03-01 Buy
Cayman Chemical 15643 Rucaparib ≥98% 283173-50-2 5mg $100 2024-03-01 Buy
Cayman Chemical 15643 Rucaparib ≥98% 283173-50-2 10mg $153 2024-03-01 Buy
Cayman Chemical 15643 Rucaparib ≥98% 283173-50-2 25mg $343 2024-03-01 Buy
TRC R701580 Rucaparib 283173-50-2 10mg $110 2021-12-16 Buy
Product number Packaging Price Buy
15643 1mg $32 Buy
15643 5mg $100 Buy
15643 10mg $153 Buy
15643 25mg $343 Buy
R701580 10mg $110 Buy

Rucaparib Chemical Properties,Uses,Production

Description

Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It was discovered as part of a collaboration between scientists working at the Northern Institute of Cancer Research and Medical School of Newcastle University and Agouron Pharmaceuticals in San Diego, California. It is being developed by Clovis Oncology.

Application

Rucaparib is used to help maintain the response to other treatments for certain types of ovarian cancer (cancer that begins in the female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and primary peritoneal (layer of tissue that lines the abdomen) cancer It is also used to treat certain types of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer in people with a specific gene who have not improved after treatment with at least two other therapies. Rucaparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by killing cancer cells.

Mechanism of action

Rucaparib inhibits "the contraction of isolated vascular smooth muscle, including that from the tumours of cancer patients. It also reduces the migration of some cancer and normal cells in culture." As a PARP inhibitor, rucaparib is expected to be more effective in the 9% of pancreatic cancers with a BRCA mutation (BRCA1 or BRCA2).

Description

Rucaparib was approved in the US as an oral treatment for advanced ovarian cancer. Development of rucaparib began with collaborations between Cancer Research UK and Agouron Pharmaceuticals (later acquired by Pfizer). Global development rights for rucaparib were ultimately granted to Clovis Oncology via a licensing agreement from Pfizer. To qualify for treatment with rucaparib monotherapy, patients must demonstrate deleterious breast cancer (BRCA) mutation (germline and/or somatic)- associated advanced ovarian cancer and also must have previously been treated with two or more chemotherapy regimens. Rucaparib functions as a small molecule poly(ADPribose) polymerase (PARP) inhibitor, which plays an important role in DNA repair. This newly approved drug displays nanomolar potency against PARP-1, -2, and -3 enzymes, which translates into improved efficacy over alternative therapies such as olaparib or niraparib. Furthermore, rucaparib is also known to cause vasodilation, which is thought to induce tumor perfusion and increased accumulation of the drug in cancer cells. Although rucaparib shows higher cytotoxicity in cancer cells with mutation of BRCA1/2 genes and other DNA repair genes, reduced tumor growth was observed in mouse xenograft models of human cancers with and without BRCA mutations.Rucaparib is also being pursued as a treatment for breast cancer and has displayed promising initial results in trials for pancreatic cancer.

Description

Poly(ADP-ribose) polymerases (PARPs) are activated by DNA single- and double-strand breaks and promote repair of DNA damage through the relaxation of chromatin and recruitment of other repair proteins. Inhibition of PARP activity has been linked to synthetic lethality in cells with mutations in BRCA1 or BRCA2 and is used as a therapeutic strategy to selectively target cancers. Rucaparib is a potent, cell-permeable inhibitor of PARP1 (Ki = <5 nM) that is used in clinical therapy to sensitize cancer cells to chemotherapy. Rucaparib inactivates PARP activity in cells with homologous recombination DNA repair pathway mutations at LC50 values ranging from 1.3-5.5 μM. At 25 mg/kg, rucaparib arrests tumor growth in mice bearing epigenetically silenced BRCA1 UACC3199 xenograft tumors. It has been shown to increase efficacy of temozolomide in medulloblastoma cells and xenografts.

Uses

Rucaparib is PARP1 inhibitor. It can be used in biological study of chemical screening to identify drugs that enhance or mitigate cellular responses to antibody-toxin fusion proteins using human B cell precursor leukemia cells and cervical adenocarcinoma cells.

Definition

ChEBI: Rucaparib is a member of the class of azepinoindoles that is 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one carrying additional 4-[(methylamino)methyl]phenyl and fluoro substituents at positions 2 and 8 respectively. It is an inhibitor of poly (ADP-ribose) polymerase and is used (as the camsylate salt) as monotherapy for advanced ovarian cancer and deleterious germline or somatic BRCA mutation. It has a role as an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor and an antineoplastic agent. It is an azepinoindole, a member of caprolactams, an organofluorine compound and a secondary amino compound. It is a conjugate base of a rucaparib(1+).

Synthesis

Synthesis of rucaparib camsylate begins from commercially available phthalimide acetal 151. Unveiling of the aldehyde via treatment with aqueous HCl and precipitation from toluene provided aldehyde 152 in 62% yield. To avoid polymerization, 152 was immediately subjected to 6-fluoro-1Hindole- 4-carboxylic acid methyl ester (153) under reductive conditions in the presence of acid to give rise to tryptamine derivative 154. After considerable research, optimal conditions for this transformation (triethylsilane in DCM/TFA) were found that were successful on up to 15.7 kg scale, enabling clean separation of the aldehyde reduction byproduct following crystallization. Conversion of the phthalimide within 154 to the corresponding amine using aqueous methylamine at room temperature was accompanied by an intramolecular cyclization reaction to secure the intermediate lactam as a solid in 89% isolated yield. This was followed by a high-yielding bromination reaction (83%) at the indole C-2 position employing pyridinium tribromide, providing access to indoloazepinone 155. After screening various catalysts for the coupling of bromide 155 and commercial boronic acid 156, Pd(dppf)Cl2?¤ DCM was found to reliably deliver the desired coupling product with reasonable rates of reaction. Thus, after development of an extensively optimized reaction protocol, Suzuki coupling of 155 and 4-formylphenylboronic acid (156) with Pd(dppf)Cl2?¤DCM and Na2CO3 in DMA at 90 ??C generated the desired 2-arylated indole 157 in high yield (92%) after trituration and reslurry with methanol. Conversion of aldehyde 157 to amine 158 necessitated a two-pot procedure designed to limit the formation of dimerization and aldehyde reduction products that generally arise under conventional onepot reductive amination conditions and have traditionally been problematic on scale. Toward this end, subjection of aldehyde 157 to a methylamine solution in EtOH/MeOH/THF and wash of the resulting reaction solids with methanol led to efficient isolation of pure imine intermediate, which could be immediately reduced with NaBH4 in THF/MeOH, providing hydrochloride salt 158 upon acidic workup in 76% over two steps. The two remaining steps for conversion to the drug involve a salt-swap, first breaking the HCl salt with NaOH in MeOH, then treatment with (S)-camphorsulfonic acid/IPA/ H2O at 70 ??C. Filtration and washing of the cake with water generated rucaparib camsylate (XVII) in 95% yield.

Synthesis_283173-50-2

1408282-26-7
699-03-6
283173-50-2
Synthesis of Rucaparib from 8-fluoro-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one and (4-BROMOBENZYL)METHYLAMINE
Global( 198)Suppliers
Supplier Tel Email Country ProdList Advantage
Zhejiang ZETian Fine Chemicals Co. LTD
+8618957127338 stella@zetchem.com China 2136 58
Capot Chemical Co.,Ltd.
+86-(0)57185586718 +86-13336195806 sales@capot.com China 29791 60
Shanghai Daken Advanced Materials Co.,Ltd
+86-371-66670886 info@dakenam.com China 18751 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21634 55
Hangzhou FandaChem Co.,Ltd.
+8615858145714 FandaChem@Gmail.com China 9087 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070 product@chemlin.com.cn CHINA 3009 60
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 - 03@ sales03@shyrchem.com CHINA 738 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32957 60
career henan chemical co
+86-0371-86658258 +8613203830695 sales@coreychem.com China 29880 58
Jinan Shengqi pharmaceutical Co,Ltd
86+18663751872 christine@shengqipharm.com CHINA 491 58

Related articles

Related Qustion

  • Q:What Rucaparib Is Used For?
  • A:Rucaparib is the generic name for the trade name drug Rubraca?. In some cases, health care professionals my use the trade name....
  • Oct 29,2019

View Lastest Price from Rucaparib manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Rucaparib pictures 2024-11-19 Rucaparib
283173-50-2
US $41.00-117.00 / mg 99.89% 10g TargetMol Chemicals Inc.
Rucaparib pictures 2022-10-01 Rucaparib
283173-50-2
US $0.00-0.00 / kg 1kg 98% 1Ton Henan Aochuang Chemical Co.,Ltd.
Rucaparib pictures 2021-07-13 Rucaparib
283173-50-2
US $15.00-10.00 / KG 1KG 99%+ HPLC Monthly supply of 1 ton Zhuozhou Wenxi import and Export Co., Ltd
  • Rucaparib pictures
  • Rucaparib
    283173-50-2
  • US $41.00-117.00 / mg
  • 99.89%
  • TargetMol Chemicals Inc.
  • Rucaparib pictures
  • Rucaparib
    283173-50-2
  • US $0.00-0.00 / kg
  • 98%
  • Henan Aochuang Chemical Co.,Ltd.
  • Rucaparib pictures
  • Rucaparib
    283173-50-2
  • US $15.00-10.00 / KG
  • 99%+ HPLC
  • Zhuozhou Wenxi import and Export Co., Ltd

Rucaparib Spectrum

8-FLUOR-2-{4-[(METHYLAMINO)METHYL]FENYL}-1,3,4,5-TETRAHYDRO-6HAZEPINO[5,4,3-CD]INDOOL-6-ON 8-fluoro-2-(4-((methylamino)methyl)phenyl)-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]- 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one 8-Fluoro-2-[4-[(methylamino)methyl]phenyl]-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Rucaparib rucaparib (PARP inhibitor) ORPHAN DRUG PF-01367388 Rucaparib impurity 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tet... AG-14447 Rucaparib free base AG-014699;PF-01367338; AG 014699;PF 01367338; AG014699;PF01367338 Rucaparib(AG-014447) Rikapbu AG014447 AG 014447;AG014447 AG 014447 8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one Rucaparib Base 8-Fluoro-2-[4-[(methylamino)methyl]phenyl]-4,5-dihydroazepino[5,4,3-cd]indol-6(3H)-one AG-14447|||PF-01367338|||AG014699 283173-50-2